We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Sanofi (SNY) Dips More Than Broader Markets: What You Should Know
Read MoreHide Full Article
In the latest trading session, Sanofi (SNY - Free Report) closed at $39.64, marking a -1.02% move from the previous day. This move lagged the S&P 500's daily loss of 0.67%. At the same time, the Dow lost 0.33%, and the tech-heavy Nasdaq lost 0.22%.
Heading into today, shares of the drugmaker had gained 0.28% over the past month, outpacing the Medical sector's loss of 1.92% and the S&P 500's loss of 3.76% in that time.
Wall Street will be looking for positivity from Sanofi as it approaches its next earnings report date. This is expected to be October 28, 2022. In that report, analysts expect Sanofi to post earnings of $1.31 per share. This would mark year-over-year growth of 1.55%. Meanwhile, our latest consensus estimate is calling for revenue of $11.99 billion, down 2.52% from the prior-year quarter.
For the full year, our Zacks Consensus Estimates are projecting earnings of $4.01 per share and revenue of $44.1 billion, which would represent changes of +3.35% and -1.16%, respectively, from the prior year.
Any recent changes to analyst estimates for Sanofi should also be noted by investors. Recent revisions tend to reflect the latest near-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook.
Our research shows that these estimate changes are directly correlated with near-term stock prices. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 3.13% lower. Sanofi currently has a Zacks Rank of #4 (Sell).
Digging into valuation, Sanofi currently has a Forward P/E ratio of 9.99. This represents a discount compared to its industry's average Forward P/E of 12.86.
We can also see that SNY currently has a PEG ratio of 1.07. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. SNY's industry had an average PEG ratio of 1.78 as of yesterday's close.
The Large Cap Pharmaceuticals industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 167, which puts it in the bottom 34% of all 250+ industries.
The Zacks Industry Rank includes is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow SNY in the coming trading sessions, be sure to utilize Zacks.com.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Sanofi (SNY) Dips More Than Broader Markets: What You Should Know
In the latest trading session, Sanofi (SNY - Free Report) closed at $39.64, marking a -1.02% move from the previous day. This move lagged the S&P 500's daily loss of 0.67%. At the same time, the Dow lost 0.33%, and the tech-heavy Nasdaq lost 0.22%.
Heading into today, shares of the drugmaker had gained 0.28% over the past month, outpacing the Medical sector's loss of 1.92% and the S&P 500's loss of 3.76% in that time.
Wall Street will be looking for positivity from Sanofi as it approaches its next earnings report date. This is expected to be October 28, 2022. In that report, analysts expect Sanofi to post earnings of $1.31 per share. This would mark year-over-year growth of 1.55%. Meanwhile, our latest consensus estimate is calling for revenue of $11.99 billion, down 2.52% from the prior-year quarter.
For the full year, our Zacks Consensus Estimates are projecting earnings of $4.01 per share and revenue of $44.1 billion, which would represent changes of +3.35% and -1.16%, respectively, from the prior year.
Any recent changes to analyst estimates for Sanofi should also be noted by investors. Recent revisions tend to reflect the latest near-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook.
Our research shows that these estimate changes are directly correlated with near-term stock prices. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 3.13% lower. Sanofi currently has a Zacks Rank of #4 (Sell).
Digging into valuation, Sanofi currently has a Forward P/E ratio of 9.99. This represents a discount compared to its industry's average Forward P/E of 12.86.
We can also see that SNY currently has a PEG ratio of 1.07. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. SNY's industry had an average PEG ratio of 1.78 as of yesterday's close.
The Large Cap Pharmaceuticals industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 167, which puts it in the bottom 34% of all 250+ industries.
The Zacks Industry Rank includes is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow SNY in the coming trading sessions, be sure to utilize Zacks.com.